Dr. Heidi T. Bloom, MD
Hand Surgery (Orthopaedic Hand Surgery Physician)
- Medicare participating
At a glance
- Medical school
- Perelman School of Med at the University of Pennsylvania (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 524
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Perelman School of Med at the University of Pennsylvania
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Orthopaedic Hand Surgery Physician primary
OR license MD24000
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Asante Rogue Regional Medical Center Medford, OR
- Asante Three Rivers Medical Center Grants PAss, OR
- Providence Medford Medical Center Medford, OR
- Fairchild Medical Center Yreka, CA
- Sutter Coast Hospital Crescent City, CA
Medical groups
- Southern Oregon Orthopedics Inc (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 524
- Services billed
- 3,335
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 707 | 105 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 408 | 113 |
| Established patient office or other outpatient visit, 20-29 minutes | 299 | 208 |
| X-ray of wrist, minimum of 3 views | 195 | 127 |
| Injection into tendon or ligament | 161 | 98 |
| Aspiration and/or injection of fluid from small joint | 149 | 92 |
| Established patient office or other outpatient visit, 30-39 minutes | 123 | 113 |
| X-ray of hand, minimum of 3 views | 93 | 56 |
| Fluoroscopic guidance for needle placement | 73 | 57 |
| New patient office or other outpatient visit, 30-44 minutes | 68 | 68 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Medford, OR | 163 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Medford, OR | 46 |
| Cephalexin Other prescribers in Medford, OR | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $139,921 in research payments for these studies, mostly to the institutions running them.
- A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
Eli Lilly and Company · Active, not recruiting · NCT04616326 - A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company · Active, not recruiting · NCT03432286 - A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396574 - A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
Eli Lilly and Company · Terminated · NCT04396236
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.